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Recent developments of tau Positron Emission Tomography (PET) allows assessment of
regional neurofibrillary tangles (NFTs) deposition in human brain. Among the tau PET
molecular probes, 18F-AV1451 is characterized by high selectivity for pathologic tau
aggregates over amyloid plaques, limited non-specific binding in white and gray matter,
and confined off-target binding. The objectives of the study are (1) to quantitatively
characterize regional brain tau deposition measured by 18F-AV1451 PET in cognitively
normal older adults (CN), mild cognitive impairment (MCI), and AD participants; (2) to
evaluate the correlations between cerebrospinal fluid (CSF) biomarkers or Mini-Mental
State Examination (MMSE) and 18F-AV1451 PET standardized uptake value ratio (SUVR);
and (3) to evaluate the partial volume effects on 18F-AV1451 brain uptake.
Methods: The study included total 115 participants (CN = 49, MCI = 58, and
AD = 8) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Preprocessed
18F-AV1451 PET images, structural MRIs, and demographic and clinical assessments
were downloaded from the ADNI database. A reblurred Van Cittertiteration method
was used for voxelwise partial volume correction (PVC) on PET images. Structural
MRIs were used for PET spatial normalization and region of interest (ROI) definition in
standard space. The parametric images of 18F-AV1451 SUVR relative to cerebellumwere
calculated. The ROI SUVR measurements from PVC and non-PVC SUVR images were
compared. The correlation between ROI 18F-AV1451 SUVR and the measurements of
MMSE, CSF total tau (t-tau), and phosphorylated tau (p-tau) were also assessed.
Results: 18F-AV1451 prominently specific binding was found in the amygdala, entorhinal
cortex, parahippocampus, fusiform, posterior cingulate, temporal, parietal, and frontal
brain regions. Most regional SUVRs showed significantly higher uptake of 18F-AV1451
in AD than MCI and CN participants. SUVRs of small regions like amygdala, entorhinal
cortex and parahippocampus were statistically improved by PVC in all groups (p < 0.01).
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Although there was an increasing tendency of 18F-AV-1451 SUVRs in MCI group
compared with CN group, no significant difference of 18F-AV1451 deposition was
found between CN and MCI brains with or without PVC (p > 0.05). Declined MMSE
score was observed with increasing 18F-AV1451 binding in amygdala, entorhinal cortex,
parahippocampus, and fusiform. CSF p-tau was positively correlated with 18F-AV1451
deposition. PVC improved the results of 18F-AV-1451 tau deposition and correlation
studies in small brain regions.
Conclusion: The typical deposition of 18F-AV1451 tau PET imaging in AD brain was
found in amygdala, entorhinal cortex, fusiform and parahippocampus, and these regions
were strongly associated with cognitive impairment and CSF biomarkers. Although
more deposition was observed in MCI group, the 18F-AV-1451 PET imaging could
not differentiate the MCI patients from CN population. More tau deposition related
to decreased MMSE score and increased level of CSF p-tau, especially in ROIs of
amygdala, entorhinal cortex and parahippocampus. PVC did improve the results of tau
deposition and correlation studies in small brain regions and suggest to be routinely used
in 18F-AV1451 tau PET quantification.
Keywords: 18F-AV1451, Tau PET, cognitively normal, mild cognition impairment, Alzheimer’s disease
INTRODUCTION
The neuropathological hallmarks of Alzheimer’s disease
(AD) are extracellular amyloid-β (Aβ) plaques and the
intraneuronal neurofibrillary tangles (NFT), which is primarily
composed of hyperphosphorylated tau protein and is a
predictor of cognition (1–3). Efforts have been devoted to
identifying and developing reliable biomarkers of different
stages of AD to differentiate the individuals who would
benefit from early intervention (4). It is well-established
in AD patients that decreased cerebrospinal fluid (CSF)
concentration of the Aβ and increased tau protein could
be used as valuable biomarkers (5, 6). CSF total tau (t-tau)
and phosphorylated tau (p-tau) improve the sensitivity and
specificity of CSF Aβ alone to identify those likely to progress
to AD dementia (7–9). Recent researches of tau Positron
Emission Tomography (PET) allowed assessment of regional
tau deposition in human brain (10–12). In vivo imaging of
tau pathology is expected to be a useful biomarker in clinical
and translational AD researches. Several PET molecular
probes, such as 11C-PBB3, 18F-THK523, 18F-THK5105, 18F-
THK5117, 18F-AV68, and 18F-AV1451, have recently been
radio-synthesized to map the tau distribution in preclinical and
clinical studies (13–18).
18F-AV1451 is characterized by high selectivity for pathologic
tau aggregates over amyloid plaques (17, 19). n vivo human
studies indicated that patterns of 18F-AV1451 retention were
paralleled with neuropathological staging of neurofibrillary
tau pathology of AD and that tracer retention increased
with age even in the presence of cognitive impairment and
dementia (18, 20, 21).
It was reported that 18F-AV1451 showed off-target binding in
caudate, putamen, pallidum and thalamus regions (19, 22, 23).
Partial volume correction (PVC) has been introduced and proved
effective in improving image quality of tau and amyloid PET as
well as accuracy and precision of the quantification analysis (21,
24–26).
In this study, we characterized regional tau deposition by
PVC-based 18F-AV1451 PET imaging in cognitively normal
older adults (CN), mild cognitive impairment (MCI) and
AD participants, and evaluated the correlations between CSF
biomarkers or Mini-Mental State Examination (MMSE) and
18F-AV1451 PET standardized uptake value ratio (SUVR). For
comparison purpose, analysis on the PET without PVC were also
included in this study.
MATERIALS AND METHODS
Data used in this article were obtained from the ADNI database
(adni.loni.usc.edu). The ADNI was launched in 2003 as a
public-private partner-ship by the National Institute on Aging,
the Food and Drug Administration, private pharmaceutical
companies and non-profit organizations. Its primary goal was
to test whether neuroimaging like serial magnetic resonance
imaging (MRI), PET, biological markers, and clinical and
neuropsychological assessment can be combined to measure the
progression of MCI and early AD (27). A detailed description of
the inclusion criteria can be found on the ADNI website (www.
adni-info.org). Data were downloaded from the ADNI database
(adni.loni.usc.edu). All participants signed written informed
consent for participation in the ADNI, as approved by the
institutional board at each participating center.
Participants
One hundred and fifteen participants with 18F-AV1451 PET, T1-
weighted magnetization-prepared rapid-acquisition gradient-
echo (MP-RAGE) or inversion recovery spoiled gradient-echo
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(IR-SPGR)MRIwere included fromADNI 1, 2. andGOdatabase.
The complete list of exclusion and inclusion criteria of ADNI
can be found online (https://adni.loni.usc.edu/wp-content/
uploads/2008/07/adni2-procedures-manual.pdf) Pre-processed
18F-AV1451 PET brain images and corresponding T1-weighted
MP-RAGE MRI images were downloaded from the ADNI
database in March 2017. The last known diagnostic status was
the one mentioned at the time of the last visit listed in the
dataset. Their clinical diagnosis was cognitively normal (CN) (N
= 49), MCI (N = 58), and AD (N = 8). Demographics, CSF
biomarkers and clinical assessments were also downloaded from
ADNI database.
PET Acquisition
The radiochemical synthesis of 18F-AV1451 was overseen and
regulated by Avid Radiopharmaceuticals and distributed to the
qualifying ADNI sites. PET imaging was performed at each
ADNI site according to standardized protocols. Eighty minutes
post-injection of about 10 mCi of 18F-AV1451 followed by the
acquisition. Data were collected as 5min per frame from 80 to
100min post-tracer injection. PET with computed tomography
imaging (PET/CT) scans preceded these acquisitions with a CT
scan for attenuation correction; PET-only scanners performed a
transmission scan following the emission scan.
MRI Acquisition
Structural MRIs were acquired at ADNI sites. All participants
had 1.5-T or 3.0-T MRI scan with a three-dimensional (3D) MP-
RAGE or IR-SPGRT1-weighted sequences with sagittal slices and
voxel size of 1.1× 1.1× 1.2 mm3. The full details were described
in online manual (http://adni.loni.usc.edu/methods/documents/
mri-protocols).
PET Processing and Quantification
T1-weighted MRI and pre-processed PET images were
downloaded from ADNI. All downloaded PET images were
pre-processed to have standard orientation, same image
volume size (160 × 160 × 96 in x, y, z) and voxel size (1.5
× 1.5 × 1.5mm in x, y, z), spatial resolution of 8mm in full
width at half maximum (FWHM) in x, y, z, respectively, by
ADNI (28). Statistical Parametric Mapping software (SPM8,
Wellcome Department of Imaging Neuroscience, London,
United Kingdom) and MATLAB (The MathWorks Inc.) were
used for further processing of the downloaded PET and MRI
images. All pre-processed mean PET images were coregistered to
structure MRI images. MRI images were normalized to standard
Montreal Neurologic Institute (MNI) space using SPM8 with
an MRI template provided by VBM8 toolbox (29, 30). PET-MRI
image processing including PET-to-MRI coregistration was
described in our previous study (31). PVC was employed to
account for partial volume effects due to brain atrophy and
signal spillover. A reblurred Van Cittertiteration method (32, 33)
was used for PVC on the mean images. For the PVC method,
a 3-D Gaussian kernel of 8mm FWHM was used for spatial
smoothing function h, step length α = 1.5, and the iteration was
stopped if relative percent change of PVC images<1% (33). Both
PVC and non-PVC mean images were coregistered to structure
MRI image for MRI-based spatial normalization. A total of 26
region of interests (ROIs) were defined on the MRI template
using PMOD software (PMOD Technologies Ltd., Zürich,
Switzerland) in the standard MNI space, and the ROI SUVRs
were calculated by using cerebellum as reference tissue with
and without PVC. A global cortex was defined as a combination
of orbital frontal, prefrontal, superior frontal, lateral temporal,
parietal, posterior precuneus, occipital, anterior cingulate, and
posterior cingulate.
Clinical and Cognitive Assessments
All participants were assessed with a wide spectrum of clinical
and cognitive tests (34). In this study, we used the global
Clinical Dementia Rating (CDR), the MMSE score, Alzheimer’s
Disease Assessment Scale-cognitive subscale (ADAS-cog 11) and
ADAS-cog 13. Neuropsychiatric symptoms were assessed by
the Neuropsychiatric Inventory Questionnaire (NPI-Q). The
depressive features and functional ability were assessed with the
Geriatric Depression Scale-Short Form (GDS) and Functional
Assessment Questionnaire (FAQ).
CSF Biomarkers Assessment
The studied variables of CSF biomarkers were Aβ, t-tau, p-tau,
the tau/Aβ, and p-tau/Aβ ratio. Apolipoprotein E (ApoE) gene
typing was carried out on all participants during the first visit.
CSF t-tau, p-tau, and Aβ42 were collected from all participants
and measured using the multiplex xMAP Luminex platform
(Luminex Corp., Austin, TX, USA) with the INNO-BIA AlzBio3
kit (Innogenetics, Ghent, Belgium) (6, 35). Full details on the
collection, processing, storage, analysis, and quality control
procedures for CSF samples can be found online (http://adni.
loni.usc.edu/methods/documents/).
Statistical Analyses
Continuous variables were presented as mean ± SD and
categorical variables as number (percent). The characteristics
of subjects were compared among CN, MCI, and AD groups
using generalized linear model (GLM) for continuous variables
and Chi-squared analysis for categorical variables. GLM was
employed in the comparison of SUVRs among CN, MCI,
and AD groups adjusted with age and education levels. The
correlations between SUVR and MMSE score, SUVR and CSF
tau biomarkers were evaluated using linear regression. SUVRs
differences between non-PVC and PVC were assessed by paired
student’s t-test. A two-sided p-value < 0.05 was considered
statistically significant. All statistical analysis was performed
using statistical package of social science (SPSS) version
24.0 software.
RESULTS
Demographics and Clinical Characteristics
Diagnostic grouping was based on the diagnosis evaluation
provided by the ADNI clinical Core. We ended up with 49 CN,
58 MCI, and 8 AD patients. The participants’ demographics,
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TABLE 1 | Demographics and clinical characteristics.
Characteristics CN MCI AD F/χ2 P-value
(N = 49) (N = 58) (N = 8) CN-MCI MCI-AD CN-AD
Sex (F/M) 24/25 16/42 5/3 7.08 0.02 0.05 0.48
Age, year 74.79 ± 6.68 77.95 ± 7.50 76.83 ± 8.74 2.53 0.07 0.91 0.74
ApoE ε4 (–/+) 30/19 38/20 2/6 4.85 0.65 0.03 0.06
Education, year 16.33 ± 2.23 16.67 ± 2.88 15.00 ± 3.02 1.46 0.78 0.22 0.39
Aβ, pg/ml 1204.80 ± 458.64 1125.76 ± 473.46 771.35 ± 200.16 2.76 0.58 0.06 0.02
t-tau, pg/ml 243.89 ± 100.53 265.77 ± 125.09 401.36 ± 123.06 5.68 0.52 0.002 <0.001
p-tau, pg/ml 22.54 ± 10.89 25.04 ± 12.33 38.89 ± 13.01 5.82 0.44 0.002 <0.001
t-tau/Aβ 0.24 ± 0.14 0.28 ± 0.19 0.55 ± 0.19 10.50 0.23 <0.001 <0.001
p-tau/Aβ 0.02 ± 0.01 0.03 ± 0.02 0.05 ± 0.02 8.17 0.14 <0.001 <0.001
ADAS_cog11 4.96 ± 2.48 9.00 ± 4.39 21.88 ± 9.66 56.08 <0.001 <0.001 <0.001
ADAS_cog13 7.76 ± 4.41 14.31 ± 6.58 33.63 ± 11.50 62.69 <0.001 <0.001 <0.001
Global CDR 0.07 ± 0.18 0.40 ± 0.26 1.06 ± 0.62 51.96 <0.001 <0.001 <0.001
NPI-Q 0.92 ± 2.52 1.55 ± 2.66 6.75 ± 4.20 15.76 0.43 <0.001 <0.001
MMSE 28.63 ± 1.82 27.66 ± 2.16 20.38 ± 4.53 46.30 0.07 <0.001 <0.001
FAQ 0.40 ± 1.76 3.18 ± 5.07 13.63 ± 9.91 29.57 0.01 <0.001 <0.001
GDScale 1.02 ± 1.18 2.03 ± 2.07 3.13 ± 1.55 7.28 0.01 0.21 0.004
ApoE type 4 allele (ApoE ε4) status, cognitive scores and CSF
biomarkers are detailed in Table 1.
The age and education years of all the participants in this
study were (76.52 ± 7.34) and (16.41 ± 2.64). No significant
differences in age and education levels were found among
CN, MCI, and AD groups. Moderate differences were found
in the proportion of sex between CN and MCI groups, and
the proportion of ApoE ε4 between MCI and AD groups,
respectively. Compared with CN and MCI participants, AD
patients were more impaired on MMSE score and performed
higher levels on CSF t-tau, p-tau, t-tau/ Aβ, p-tau/ Aβ,
ADAS-cog 11, ADAS-cog 13, Global CDR, NPI-Q, and FAQ
scores (p < 0.01). There was no significant difference on
levels of all CSF biomarkers between CN and MCI group
(all p > 0.05).
Brain Tau Deposition in CN, MCI, and AD
Participants
PVC for this study was used to decrease off-target binding in
choroid plexus close to the hippocampus, basal ganglia, and
brain atrophy. In order to create an anatomical visualization of
the effects of PVC on spatial resolution and image contrast, we
displayed mean 18F-AV1451 SUVR images of CN, MCI, and AD
with and without PVC in Figure 1, which clearly showed an
increased image spatial resolution and contrast after PVC inmost
cortical and subcortical ROIs. Brain 18F-AV1451 SUVR patterns
were visually consistent with previous post-mortem and in vivo
PET studies (1, 20, 21).
GLM was used in the comparison of SUVRs of ROIs
between and among groups and adjusted with age and education
levels. The highest deposition regions of 18F-AV1451 among the
26 ROIs were amygdala, entorhinal cortex, parahippocampus,
fusiform, and posterior cingulate. More deposition was observed
in parietal, posterior precuneus and frontal cortex, whereas
less concentration in hippocampus and occipital brain regions.
For AD participants, there were significantly more 18F-AV1451
retention in amygdala, entorhinal cortex, parahippocampus,
superior frontal cortex, medial temporal cortex, and parietal
cortex than CN and MCI participants (all p < 0.01), which was
shown in Figure 2. The average SUVRs of entorhinal cortex,
amygdala and parahippocampus in CN group were 1.27, 1.26,
and 1.18, respectively. In comparison, they were 1.32, 1.33, and
1.21 in MCI group, respectively. Increased SUVRs were observed
with PVC studied. Although there was an increasing tendency
of SUVRs in MCI group, no statistical different was found in all
ROIs between CN and MCI participants with or without PVC
(p > 0.05).
Notably, these results were observed in both PVC and
non-PVC studies. The entorhinal cortex SUVR in AD group
with or without PVC was 1.97 vs. 1.69, which showed a 18%
promotion in quantitative analysis. In regions of amygdala,
PVC improved almost 20% of the SUVR. These results were
observed in many small regions not only in AD group
but also in MCI and CN group. Using paired student’s t-
test, 22 of the 26 ROIs showed statistical difference with or
without PVC. Of note, SUVRs of small regions like amygdala,
entorhinal cortex, and parahippocampus were statistically
improved by PVC in all groups (p < 0.01), which were shown
in Figure 3.
Correlations Between Regional 18F-AV1451
SUVRs and MMSE Score, and Between
18F-AV1451 SUVRs and CSF
Tau Biomarkers
We found thatMMSE score, CSF t-tau, and p-tau in 15 ROIs were
significantly associated with the ROI-based 18F-AV-1451 SUVR
Frontiers in Neurology | www.frontiersin.org 4 May 2019 | Volume 10 | Article 486
Zhao et al. Quantitative 18F-AV1451 Tau PET
FIGURE 1 | 18F-AV1451 SUVR Mean Images with PVC and non-PVC. Mean images generated by computing the mean of images from AD, MCI, and CN participants
separately. The upper images have been corrected with PVC, whereas the lower images without PVC.
(p < 0.05). Increasing 18F-AV1451 retention was significantly
related with decreasing MMSE score and increasing CSF p-tau.
The correlations of MMSE and the ROI SUVRs with PVC were
shown in Figure 4.
For example, the correlation coefficient between amygdala
SUVR and MMSE score was −0.60, which was statistically
different (p < 0.001). The correlation coefficient between
entorhinal cortex SUVR and CSF p-tau value was 0.48, which was
also statistically different (p < 0.001). Notably, the correlation
between ROI SUVRs and MMSE score and between ROI SUVRs
and CSF tau biomarkers were observed in both PVC and non-
PVC studies. Similar with deposition study of 18F-AV-1451, PVC
improved the correlation study, especially in small brain regions.
The correlations of CSF p-tau and the ROI SUVRswith PVCwere
shown in Figure 5.
DISCUSSION
In this study, we summarized the deposition pattern of 18F-
AV1451 in CN,MCI, and AD brains and assessed the ROI SUVRs
of 18F-AV1451 association with clinical cognitive measures and
CSF biomarkers in CN, MCI, and AD participants. PVC was
used as a routine method and age and education level were also
included as covariates in this study.
The main finding of this study was that although there was
an increasing tendency of 18F-AV1451 SUVRs in MCI group
compared with CN group, no significant difference of 18F-
AV1451 deposition was found between CN and MCI brains
with or without PVC. We confirmed that more tau deposition
related to decreased MMSE score and increased level of CSF
p-tau, especially in ROIs of amygdala, entorhinal cortex, and
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FIGURE 2 | 18F-AV1451 SUVRs of cortical and subcortical ROIs in AD, MCI, and CN groups. Bar graphs showing ROIs SUVR (mean with error bars depicting SD)
comparison among AD, MCI and CN groups in the orbitofrontal cortex (A), prefrontal cortex (B), superior frontal cortex (C), lateral temporal cortex (D), medial
temporal cortex (E), parietal cortex (F), posterior central cortex (G), posterior precuneus (H), posterior cingulate (I), global cortex (J), entorhinal cortex (K), amygdala
(L), parahippocampus (N) and fusiform (M). P-value was defined using GLM to compare SUVR between CN and MCI, CN and AD, MCI and AD. *p < 0.05, **p <
0.01, ***p < 0.001.
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FIGURE 3 | Representative 18F-AV1451 SUVRs comparison with or without PVC. Bar graphs showing ROIs SUVR (mean with error bars depicting SD) comparison
between PVC and non-PVC in entorhinal cortex (A), amygdala (B) and parahippocampus (C). P-value was defined using paired t-test to compare SUVR between
PVC and non-PVC images in CN, MCI, and AD groups. **p < 0.01, ***p < 0.001.
parahippocampus. PVC improved the results of 18F-AV1451 tau
deposition and correlation studies in small brain regions.
The differences among CN, MCI, and AD participants were
highly significant for ApoE ε4 status, cognition and four CSF
markers, except for Aβ level. It is widely reported that ApoE ε4
genotype is one of the major risk factors in AD. In this study, 75%
of AD participants were ApoE ε4 carriers. Also, we got the similar
result that the females are more likely to develop AD compared
with the males, and education years are not declined with the
cognitive function as reported (36, 37). The level of CSF t-tau and
p-tau could reflect the tau deposition in brain to some extent. We
also found that CSF t-tau and p-tau levels in AD participants were
significantly higher than MCI and CN participants.
One of the earliest regions to degenerate to AD and the
first tau deposition region is the mesial temporal lobe (1).
Because of the retention in temporal lobe in normal aging
adults as reported (21), we included age and education level as
covariant for comparison of ROI 18F-AV1451 SUVRs among
different groups. Our major findings in ROI-based SUVRs
were as follows: increased 18F-AV1451 prominently deposit
in entorhinal cortex, amygdala, parahippocampus, fusiform, as
well as posterior cingulate and temporal brain region, followed
by parietal and frontal brain regions, and to a less degree
in the hippocampus and occipital brain regions in the full
cohort, which were similar in previous reports (38). Scholl
et al. focused on the uptake of 18F-AV1451 in participants
with different PiB status and found localized and increased
uptake of 18F-AV1451 in temporal lobe regions, medial temporal
subregions and partly in inferior and lateral temporal cortical
regions in PiB-negative old healthy adults. AD patients showed
higher retention of 18F-AV1451 particularly throughout temporal
lobe to encompass a larger region of parietal and frontal cortex
(21). Cho et al. reported 18F-AV1451 tau PET accumulation
most frequently observed in the medial temporal regions and
stepwise spread to basal and lateral temporal, inferior parietal,
posterior cingulate, and the other association cortices (39). They
also found tau accumulation was most frequently deposited in
the entorhinal cortex and parahippocampal cortex, then involved
in the fusiform, inferior temporal cortex, amygdala, middle
temporal, inferior parietal, posterior cingulate. Like postmortem
and other different cohorts’ study (2, 40), the entorhinal
cortex was the most frequently involved region followed by
adjacent limbic areas (amygdala and parahippocampus) in
our study.
Johnson et al. found a higher 18F-AV1451 binding inMCI/AD
group compared with CN group in entorhinal cortex and
parahippocampus (20). In this study we compared the difference
of SUVRs between CN and MCI participants. Of all the
ROIs, none of the SUVRs was statistically different between
CN and MCI in our study. However, these regions can be
easily distinguished: orbital frontal, prefrontal, superior frontal,
lateral temporal, medial temporal, parietal, posterior precuneus,
posterior cingulate, global cortex, amygdala, entorhinal, fusiform,
and parahippocampus. Although there was no significant
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FIGURE 4 | Correlation of MMSE and 18F-AV1451 deposition in ROI SUVRs with PVC. Correlation of MMSE and ROI SUVRs with PVC in the orbitofrontal cortex (A),
prefrontal cortex (B), superior frontal cortex (C), lateral temporal cortex (D), medial temporal cortex (E), parietal cortex (F), posterior central cortex (G), posterior
precuneus (H), posterior cingulate (I), occipital cortex (J), global cortex (K), entorhinal cortex (L), amygdala (M), fusiform (N) and parahippocampus (O).
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FIGURE 5 | Correlation of CSF p-tau level and 18F-AV1451 deposition in ROI SUVRs with PVC. Correlation of CSF p-tau level and ROI SUVRs with PVC in the
orbitofrontal cortex (A), prefrontal cortex (B), superior frontal cortex (C), lateral temporal cortex (D), medial temporal cortex (E), parietal cortex (F), posterior central
cortex (G), posterior precuneus (H), posterior cingulate (I), occipital cortex (J), global cortex (K), entorhinal cortex (L), amygdala (M), parahippocampus (N) and
fusiform (O).
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difference between MCI and CN group, there was still a
clear increasing trend for tau binding. For example, SUVR in
entorhinal cortex was 1.39 in CN, but it was 1.48 in MCI brain.
When compared with CN brain, SUVRs in MCI brain increased
by 2–9%.
It was reported that PVC has improved the tau PET
quantification (23, 41). To deal with off-target binding and brain
atrophy on PET quantification, we performed the PVC routinely
in this study. In CN group, 85% ROIs were statistically different
with or without PVC. However, the percentage fell to 73 and
35% in MCI and AD group, respectively. PVC showed better
adjustment of SUVRs, especially in CN group. As visualized
directly in 18F-AV1451 SUVR mean image, PVC improved the
spatial resolution and image contrast. The amygdala SUVR
with or without PCR in AD brain was 1.66 and 1.99, which
almost increased by 20% after PVC. In comparison of SUVRs
of posterior precuneus region between MCI and AD group, the
statistical status was evenly changed.
In all participants, SUVRs of substantia nigra, ventral
striatum and putamen were at a higher level, but no statistical
differences among groups were observed. This could be due to
the off-target binding of 18F-AV1451, brain atrophy and tau
accumulation in neurodegeneration. Hippocampal 18F-AV1451
SUVR in all three groups were more than 1.2. However,
there was no significant increase in the AD progression in
this study, and this will be studied and verified by a large
population, especially more AD patients enrolled, with going
ADNI project.
We also observed a significant relationship between MMSE
score and 18F-AV1451 SUVR. In this study, declined MMSE
score was observed with increasing 18F-AV1451 binding in
amygdala, entorhinal cortex, parahippocampus, and fusiform
as shown in Figure 4, which was paralleled with cognitive
impairment and AD progression. Besides cognitive status, we
also found significant association between the ROI SUVRs and
CSF t-tau and p-tau level, which was similar to the previous
reports (20). Mattsson et al. evaluated the performance of 18F-
AV1451 PET imaging and CSF tau in different clinical stages
of AD and found that 18F-AV1451 exhibited closely to perfect
diagnosis in mild and moderate AD (42). As CSF p-tau is
a biomarker of AD, we also observed a positive correlation
between CSF p-tau level and 18F-AV1451 deposition as seen
in Figure 5. Ascending 18F-AV1451 deposition in cortical and
subcortical ROIs, especially in amygdala, entorhinal cortex,
fusiform, and parahippocampus, were observed with more
pathological tau deposition in brain. The correlation results
of MMSE and regional 18F-AV1451 binding was partially
consistent with previous study, which evaluated the correlation
between inferior temporal 18F-AV1451 binding and MMSE in
all participants, CN and MCI/AD group (20). The rho value
in all participants was −0.46. In this study the rho value
of amygdala 18F-AV1451 SUVR and MMSE score was −0.60
(p < 0.001, Figure 4M), and the rho value of entorhinal
cortex 18F-AV1451 binding and CSF p-tau level was 0.48 (p
< 0.001, Figure 5L). We routinely applied PVC to account
for off-target binding and atrophy effects. When we examined
correlations between non-PVC SUVRs and MMSE score,
although correlations were weaker, the overall pattern of results
were consistent.
CONCLUSIONS
The typical deposition of 18F-AV1451 tau PET imaging in AD
brain was found in amygdala, entorhinal cortex, fusiform and
parahippocampus, and these regions were strongly associated
with cognitive impairment and CSF biomarkers. Although more
deposition was observed in MCI group, the 18F-AV-1451 PET
imaging could not differentiate the MCI patients from CN
population. More tau deposition related to decreased MMSE
score and increased level of CSF p-tau, especially in ROIs of
amygdala, entorhinal cortex, and parahippocampus. PVC did
improve the results of tau deposition and correlation studies
in small brain regions and is suggested to be routinely used in
18F-AV1451 tau PET quantification.
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